

## Lipum secures an EUR 8 million Horizon Europe grant

**Lipum has signed the grant agreement for BEYOND, a project selected by Horizon Europe under the call “Boosting the translation of biotech research into innovative health therapies”. The project has been awarded a total grant of approximately EUR 8 million, of which Lipum’s share is approximately EUR 5.5 million. The funding will support the continued clinical development of SOL-116, including a planned Phase IIa proof-of-concept study in patients with moderate to severe rheumatoid arthritis (RA).**

The project will be led by Lipum and carried out in collaboration with a European consortium consisting of Age Labs AS, Centre for Human Drug Research (CHDR) and MERAccess AB. Together, the partners bring expertise in clinical development, biomarker analysis, health economics and market access.

BEYOND is designed to generate clinical proof-of-concept data for SOL-116 in RA and to strengthen the scientific and health-economic evidence needed to support further development.

“We are very pleased to have signed the Horizon Europe grant agreement for BEYOND and to take the next step in the clinical development of SOL-116 together with our partners. This support is a very important recognition of the project and its potential for patients with RA. I would like to thank the European Commission, our partners Age Labs, CHDR and MERAccess, and all our employees for making this possible,” says Ola Sandborgh, CEO of Lipum.

With the BEYOND funding in place, Lipum is now positioned to take SOL-116 into its next important clinical stage and further explore its potential as a new treatment option for RA.

SOL-116 is being developed for chronic inflammatory diseases and is based on a novel approach that selectively targets Bile Salt-Stimulated Lipase (BSSL), a protein implicated in inflammatory processes. In a completed First-in-Human Phase I trial, SOL-116 demonstrated robust results, including a favorable safety profile, predictable pharmacokinetics supporting once-monthly dosing, low immunogenicity and confirmed target engagement.

These results provide a solid foundation for the planned Phase IIa proof-of-concept study, where the efficacy of SOL-116 will be evaluated in a clinically relevant RA setting.

### Contacts

Ola Sandborgh, CEO

[ola.sandborgh@lipum.se](mailto:ola.sandborgh@lipum.se)

+46 72 218 80 21

Web: [www.lipum.se](http://www.lipum.se)

**PRESS RELEASE**

02 July 2026 10:35:00 CEST



**About Us**

Lipum AB is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical phase with a successfully completed Phase 1 study. Together with strong preclinical data, we have a solid foundation for continued development in the treatment of rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant.

**Attachments**

[Lipum secures an EUR 8 million Horizon Europe grant](#)